middle.news
Can Cleo Diagnostics Turn $4M Loss into Ovarian Cancer Test Breakthrough?
11:46pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
Can Cleo Diagnostics Turn $4M Loss into Ovarian Cancer Test Breakthrough?
11:46pm on Friday 29th of August, 2025 AEST
Key Points
Loss widened to $3.999 million in FY2025
Progress on FDA 510(k) submission and pivotal US clinical trial
Completed prototype assay testing and manufacturing scale-up
Secured access to major ovarian cancer biobanks (UKCTOCS, PLCO)
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE